Novartis AG, in a bid to bolster its Sandoz business amid consolidation in the industry, is said to be looking to acquire generic-drugs maker Amneal Pharmaceuticals LLC, according to Bloomberg.
Amneal, which could be valued at $8 billion in a sale, reportedly is exploring options through an adviser.
Click here to see the Bloomberg report…
Filed Under: Drug Discovery
